Skip to main content

Table 4 Treatments administered in ICU and outcomes

From: Seasonal burden of severe influenza virus infection in the critically ill patients, using the Assistance Publique-Hôpitaux de Paris clinical data warehouse: a pilot study

Variable

All participants

n = 320

Survivors

n = 257

Non-survivors

n = 63

Organ support and additional therapies, n (%)

 Mechanical ventilationa

182 (56.9)

136 (52.9)

46 (73.0)

 Invasive mechanical ventilation

116 (36.2)

77 (30.0)

39 (61.9)

 Neuromuscular blocking agents

17 (5.3)

13 (5.1)

4 (6.3)

 Prone positioning

35 (10.9)

23 (8.9)

12 (19.0)

 NO

17 (5.3)

13 (5.1)

4 (6.3)

 ECMO

6 (1.9)

3 (1.2)

3 (4.8)

 Vasopressors

100 (31.2)

62 (24.1)

38 (60.3)

 Renal replacement therapy

39 (12.2)

22 (8.6)

17 (27)

 Steroidsb

67 (20.9)

52 (20.2)

15 (23.8)

 Oseltamivirc

278 (86.9)

232 (90.3)

46 (73.0)

Length of stay (days), median [IQR]

 ICU

8 [4–15]

8 [4–15]

7 [2–15.5]

 Hospital

15 [8–28]

16 [9–31]

10 [3.5–18.5]

  1. NO nitric oxide, ECMO extracorporeal membrane oxygenation
  2. aInvasive mechanical ventilation with endotracheal intubation, non-invasive positive pressure ventilation and high flow nasal oxygen therapies were included in the category mechanical ventilation
  3. bSteroids included hydrocortisone and methylprednisolone
  4. cOseltamivir was either continued (n = 76) or introduced within the first 24 h of ICU/ICW referral (n = 202)